GAMMA Investing’s Cytek Biosciences CTKB Stock Holding History

GAMMA Investing’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.38K	Buy	1,239 +250	+25%	+$1.19K	﹤0.01%	3495
2026 Q2	$4.38K	Sell	989 -642	-39%	-$2.74K	﹤0.01%	3523
2026 Q1	$7.13K	Buy	1,631 +1,114	+215%	+$5.26K	﹤0.01%	3226
2025 Q4	$2.61K	Buy	+517	New	+$2.4K	﹤0.01%	3527
2025 Q2	–	Sell	-718	Closed	-$2.88K	–	3797
2025 Q1	$2.88K	Sell	718 -4,214	-85%	-$21.8K	﹤0.01%	3295
2024 Q4	$32K	Buy	4,932 +3,635	+280%	+$21.7K	﹤0.01%	2002
2024 Q3	$7.18K	Buy	1,297 +229	+21%	+$1.3K	﹤0.01%	2590
2024 Q2	$5.96K	Buy	1,068 +172	+19%	+$1.03K	﹤0.01%	2498
2024 Q1	$6.01K	Sell	896 -704	-44%	-$5.57K	﹤0.01%	2320
2023 Q4	$12.1K	Buy	+1,600	New	+$10.1K	﹤0.01%	1799

Other funds holding CTKB

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

DCM

Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

GWM

Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return

GAMMA Investing's CTKB Position: Q3 2026 in Review

GAMMA Investing increased its Cytek Biosciences (CTKB) stake by 25% in Q3 2026, buying an estimated $1.19K and bringing the position to 1,239 shares worth $7.38K. The position accounts for ﹤0.01% of the portfolio, ranked #3495.

GAMMA Investing first reported a position in CTKB in Q4 2023 and has held it in 10 quarters since. The position peaked at $32K in Q4 2024. 9 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

GAMMA Investing held 1,239 shares of Cytek Biosciences worth $7.38K as of Q3 2026.
GAMMA Investing bought 250 Cytek Biosciences shares in Q3 2026, an estimated $1.19K.
Cytek Biosciences made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3495 holding.
GAMMA Investing first reported a position in Cytek Biosciences in Q4 2023 and has held it in 10 quarters since.
GAMMA Investing's Cytek Biosciences position peaked at $32K in Q4 2024.
9 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.